Published in Ann Clin Transl Neurol on June 23, 2016
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (1991) 9.89
Creatine and creatinine metabolism. Physiol Rev (2000) 5.76
Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology (1968) 3.48
Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr (1990) 3.24
Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron (2002) 2.98
Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. Am J Clin Nutr (2002) 2.96
Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis (2001) 2.42
Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol (2008) 2.35
Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.33
X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain (1989) 2.10
Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci (2006) 2.07
Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest (2006) 1.67
Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain (2006) 1.57
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53
The role of phosphorylcreatine and creatine in the regulation of mitochondrial respiration in human skeletal muscle. J Physiol (2001) 1.50
Excitation-contraction coupling in skeletal muscle: comparisons with cardiac muscle. Clin Exp Pharmacol Physiol (2000) 1.47
Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol (2009) 1.43
Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle (2012) 1.42
Validation of body composition by dual energy X-ray absorptiometry (DEXA). Clin Physiol (1991) 1.41
Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci (2007) 1.20
Lower limb skeletal muscle mass: development of dual-energy X-ray absorptiometry prediction model. J Appl Physiol (1985) (2000) 1.11
Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol (2012) 1.10
Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol (1992) 1.08
Kennedy disease. J Inherit Metab Dis (1997) 1.06
Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study. Magn Reson Imaging (2010) 0.98
Creatine transporter and mitochondrial creatine kinase protein content in myopathies. Muscle Nerve (2001) 0.90
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol (2014) 0.89
Brugada syndrome in spinal and bulbar muscular atrophy. Neurology (2014) 0.88
Tongue pressure as a novel biomarker of spinal and bulbar muscular atrophy. Neurology (2013) 0.85
A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study. Neuromuscul Disord (2015) 0.85
Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain (2012) 0.84
Estimation of total body skeletal muscle mass in Chinese adults: prediction model by dual-energy X-ray absorptiometry. PLoS One (2013) 0.83
Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum (1995) 0.83
Relation between plasma creatinine and body size. Clin Chem (1986) 0.82
Creatine for treating muscle disorders. Cochrane Database Syst Rev (2007) 0.82
Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors. Hum Mol Genet (2014) 0.82
The expanding role for chromatin and transcription in polyglutamine disease. Curr Opin Genet Dev (2014) 0.81
Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov Disord (2014) 0.80
Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy. J Neurol (2011) 0.77